Article Text

Download PDFPDF

#947 Immunohistochemical markers of endometrial cancer of different morfological forms
  1. Serhii Kartashov,
  2. Kateryna Oleshko and
  3. Maryna Kartashova
  1. Educational and scientific institute of postgraduate education of KNMU, Kharkiv, Ukraine


Introduction/Background Introduction. Endometrial cancer is one of the most common forms of oncopathology in developed countries. A search is underway for molecular biological markers that will allow us to identify new approaches to the treatment of pathology with better results.

Methodology In 61 patients with endometrial cancer (EC) stage I-IV, immunohistochemical (IHC) method in tumor cells determined: the presence of microsatellite instability (MSI) and the expression of Ki 67, Bcl 2, estrogen receptors (ER), progesterone receptors (RP).

Results It has been established that various morphological forms of EC have fundamental differences in IHC markers: endometrioid forms are characterized by a high level of expression of RP, ER and Bcl 2 in combination with a low expression of Ki 67. Non-endometrioid forms of EC have a significantly higher proliferative activity, in the absence or minimal expression of receptors. The correlation of MCH tumor status with markers is more significant for endometrioid forms of EC: MCH+ tumors were characterized by lower proliferative activity and a tendency to greater expression of RP, ER, and Bcl 2, compared with MCH-negative phenotype. In non-endometrioid forms of MCH+, ECs had a significantly higher expression of Bcl 2 in combination with a high level of Ki 67 and low (RP) or absence (RE) hormone receptors, which reduces the prognostic significance of the MSI-negative tumor phenotype.

Conclusion For endometrioid forms of EC, it is advisable to use a complex of markers, including MSN, ER, RP, and Ki 67. For non-endometrioid forms, the markers Ki 67 and Bcl 2 are more informative.

Disclosures Evaluation of molecular and biological parameters is prognostically important in the treatment of endometrial cancer.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.